Keeping Track: US FDA Shoots Down Lilly's Baricitinib, Approves Neurocrine's Ingrezza

 
• By Bridget Silverman

The latest drug development news and highlights from our FDA Performance Tracker.

Keeping Track Feature image

More from Approvals

More from Product Reviews